Physician profile
Daniel K Mccammon
NPI 1073518890
$9,066.41
in general payments reported to CMS, 2019-2025
52 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $1,746 · 2021: $876 · 2022: $1,422 · 2023: $1,228 · 2024: $1,587 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,666.75 | 2020-2022 | |
| Novo Nordisk INC | $1,309.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $724.76 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $605.09 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $447.34 | 2019-2025 | Jardiance, Mounjaro, Humulin |
| Insulet Corporation | $428.28 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $387.91 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $344.61 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $328.58 | 2019-2025 | Tepezza, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $299.12 | 2021-2025 | |
| Corcept Therapeutics | $274.46 | 2019-2025 | Korlym |
| Mannkind Corporation | $209.09 | 2019-2024 | Afrezza |
| Medtronic Minimed, INC. | $143.74 | 2019-2020 | |
| Horizon Therapeutics Plc | $142.07 | 2021-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $138.92 | 2022-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mccammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.